BONESUPPORT AB Announces New Drilling Performance Capability For CERAMENT™|BONE VOID FILLER

LUND, Sweden, March 11, 2014 /CNW/ - BONESUPPORT, an emerging leader in injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, announced today that a new drilling performance capability for CERAMENT™|BONE VOID FILLER is now reflected in the product's Instructions for Use (IFU). The new claim allows for safe and effective drilling of CERAMENT™ during orthopedic surgical procedures.

"Over the past two years, we have experienced significant growth with CERAMENT™|BONE VOID FILLER," said Lloyd Diamond, CEO of BONESUPPORT. "This rapid adoption has led to an increased interest in expanded indications, including the ability to drill through CERAMENT™. We have conducted a series of rigorous testing to ensure the integrity of the product and are proud to be able to meet this important market need."

"We've seen good results using CERAMENT™|BONE VOID FILLER," said Charles Moon, M.D., Associate Director, Orthopaedic Trauma, Cedars-Sinai. "The ability to effectively drill through CERAMENT™ provides surgeons with the confidence to expand use of this novel product."

CERAMENT™|BONE VOID FILLER is FDA cleared as a filler for gaps and bone voids for orthopedic applications. CERAMENT™ is naturally resorbed by the body and is replaced by bone during the healing process. Studies have shown that new bone remodels within 6-12 months following treatment with CERAMENT™|BONE VOID FILLER.

"The addition of drilling to CERAMENT's performance capabilities is a great compliment to a product that already offers easy mixing and flexible handling," said Aimee S. Klapach, M.D., an orthopedic surgeon practicing in Minneapolis, MN, and a graduate of the prestigious Hospital for Special Surgery (HSS) in New York City. "We've seen excellent results to date and look forward to incorporating CERAMENT™ into more of our orthopedic procedures."

About BONESUPPORT

BONESUPPORT is an emerging leader of injectable bone graft substitutes for orthopedic trauma focusing on bone infection, instrument augmentation and spinal applications. CERAMENT™ is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery. CERAMENT's unique biologic properties deliver a consistent, pre-packed and ready-to-use formulation to facilitate optimal delivery. CERAMENT™|G is the first CE-marked injectable antibiotic eluting ceramic bone graft substitute. CERAMENT™|G is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries. CERAMENT™|G is not available in the United States.

CERAMENT™ is a fully developed product platform that is commercially available in the U.S. and Europe and is revolutionizing the treatment of fragility and other fractures caused by disease and trauma. Scientific research of CERAMENT spans more than eleven years. Over forty-five pre-clinical, clinical and animal studies have been conducted and close to 9,000 patients have been treated with CERAMENT. The company was founded in 1999 and is based in Lund, Sweden with subsidiary locations in the US and Germany. To learn more about BONESUPPORT please visit www.bonesupport.com.

Press Inquiries:
Offer Nonhoff
Chief Financial Officer
[email protected]
Phone [phone]

PR 0342-01 EN

SOURCE: BONESUPPORT

http://www.bonesupport.com